ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

ClinicalTrials.gov ID: NCT06625320

Public ClinicalTrials.gov record NCT06625320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study identification

NCT ID
NCT06625320
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Revolution Medicines, Inc.
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

  • 5-fluorouracil Drug
  • Gemcitabine Drug
  • Irinotecan Drug
  • Liposomal irinotecan Drug
  • Oxaliplatin Drug
  • RMC-6236 Drug
  • leucovorin Drug
  • nab-paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 15, 2024
Primary completion
May 31, 2026
Completion
Nov 30, 2027
Last update posted
Apr 26, 2026

2024 – 2027

United States locations

U.S. sites
37
U.S. states
22
U.S. cities
34
Facility City State ZIP Site status
Banner MD Anderson Cancer Center Gilbert Arizona 85234
Mayo Clinic Cancer Center - Phoenix Phoenix Arizona 85054
City of Hope-Duarte Duarte California 91010
Cedars-Sinai Medical Center Los Angeles California 90048
UCLA Los Angeles California 90095
UC San Diego Health Moores Cancer Center San Diego California 92037
Mission Hall UCSF San Francisco California 94158
Rocky Mountain Cancer Aurora Colorado 80012
Mayo Clinic Cancer Center - Florida Jacksonville Florida 32224
University of Miami Sylvester Comprehensive Cancer Center Miami Florida 33136
Cancer Care Centers of Brevard Inc Palm Bay Florida 32909
Moffitt Cancer Center Tampa Florida 33612
The Queen's Medical Center Honolulu Hawaii 96813
The University of Chicago Medical Center Chicago Illinois 60637
Johns Hopkins Baltimore Maryland 21287
Dana Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Ann Arbor Michigan 48109
Karmanos Cancer Institute Detroit Michigan 48201
Mayo Clinic Cancer Center - Rochester Rochester Minnesota 55905
Washington University St Louis Missouri 63110
Roswell Park Cancer Institute Buffalo New York 14263
NYU Lagone Health New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10022
Columbia University Medical Center New York New York 10032
Duke University Medical Center Durham North Carolina 27710
University of Cincinnati Medical Center Cincinnati Ohio 45219
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Oregon Health and Science University Portland Oregon 97239
Abramson Cancer Center Clinical Research Unit Philadelphia Pennsylvania 19104
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
Sarah Cannon Research Institute (Tennessee) Nashville Tennessee 37203
Texas Oncology Sammons Dallas Texas 75246
MD Anderson Cancer Center Houston Texas 77030
Texas Oncology - Central South Irving Texas 75063
Huntsman Cancer Institute Salt Lake City Utah 84112
Virginia Cancer Specialists Fairfax Virginia 22031
Fred Hutchinson Cancer Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06625320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 26, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06625320 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →